February 9, 2021 -- WuXi Biologics said that its MFG5 drug-substance manufacturing facility in China has initiated good manufacturing practices (GMP)-compliant operation on a 36,000-L biomanufacturing line.
The deployment of nine 4,000-liter single-use bioreactors brings the company's current biomanufacturing capacity to 90,000 liters, according to the vendor. WuXi Biologics said that its 70,000-sq-m facility is the largest drug substance facility within its global network. The company also claims that the site is the largest GMP facility in the world using single-use bioreactors.
WuXi Biologics also noted that it plans to roll out an additional 24,000 L in GMP-ready biomanufacturing capacity to the MFG5 facility with the launch of 12 2,000-L single-use bioreactors in the second half of 2021.
Copyright © 2021 scienceboard.net